ELDN — Eledon Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $235.14m
- $157.50m
Annual income statement for Eledon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 36.9 | 88.4 | 43 | 70.6 | 83.3 |
| Operating Profit | -36.9 | -88.4 | -43 | -70.6 | -83.3 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -36.9 | -88 | -117 | -35.8 | -45.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -34.5 | -88 | -117 | -36.2 | -45.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34.5 | -88 | -117 | -36.2 | -45.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34.5 | -88 | -117 | -36.2 | -45.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.33 | -2.75 | -4.73 | -0.745 | -0.557 |